WHO Pharmaceuticals Newsletter 2003, No. 04
(2003; 13 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentATYPICAL ANTI-PSYCHOTICS - Reports of hypertension
Afficher le documentBOTULINUM A - Patients misled over safety
Afficher le documentCHELIDONIUM MAJUS - Statement to advise use under supervision
Afficher le documentCYCLO-OXYGENASE (COX)-2 INHIBITORS - Reports of hepatotoxicity
Afficher le documentETONOGESTREL - Vaginal bleeding with sub-dermal implant
Afficher le documentFLUTICASONE - ADR update
Afficher le documentGATIFLOXACIN - Reports of abnormal glucose metabolism
Afficher le documentHORMONE REPLACEMENT THERAPY (HRT) - ‘Million Women Study’ confirms breast cancer association
Afficher le documentMEDROXY-PROGESTERONE - Reports of contraception failure with depot preparations
Afficher le documentMEFLOQUINE - Patient guide warns of psychiatric adverse events
Afficher le documentMETHOTREXATE - New solutions to prevent fatalities/adverse events
Afficher le documentMINOCYCLINE - Hepatic reactions
Afficher le documentPIPERACILLIN - Serum methotrexate monitoring advised during concomitant therapy
Afficher le documentRIFAMPICIN & PYRAZINAMIDE - Warning against use in latent tuberculosis
Afficher le documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia
Afficher le documentSIBUTRAMINE - Serotonin syndrome
Afficher le documentTICLOPIDINE - No decrease in ADR reports
Afficher le documentVIGA/VIGA FOR WOMEN - Presence of sildenafil
Afficher le documentWARFARIN & MICONAZOLE - Reminder about interaction
Ouvrir ce répertoire et afficher son contenuDRUGS IN THE NEWS
 

SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia

Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) has now received a total of 311 reports of hyponatraemia associated with the use of SSRIs and venlafaxine; in 67 of these reports the patient also had the syndrome of inappropriate antidiuretic hormone secretion. An SSRI was the only suspected drug in more than two-thirds of the 311 reports, although a small proportion (14%) of cases involved the concurrent use of a diuretic. The majority (75%) of patients were women and most (85%) were older than 60 years (mean age 77 years). Hyponatraemia usually occurred within the first 30 days of use and in many cases was the only abnormality reported, with a median serum sodium nadir of 120 mmol/L (range 113-133). Approximately two-thirds of cases recovered fully after withdrawal of the SSRI and fluid restriction, but three cases had a fatal outcome.

Reports in WHO-file: SSRIs: Hyponatraemia 2381

Reference:

Adverse Drug Reactions Advisory Committee (ADRAC).
Hyponatraemia with SSRIs. Australian Adverse Drug Reactions Bulletin 22: 10, Jun 2003.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013